File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands

TitleAnticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands
Authors
Keywordsgold(III)
porphyrin
N-heterocyclic carbene
anticancer
biomolecular target
Issue Date2020
PublisherFrontiers Media SA. The Journal's web site is located at http://www.frontiersin.org/chemistry
Citation
Frontiers in Chemistry, 2020, v. 8, p. article no. 587207 How to Cite?
AbstractThe use of gold in medicine has a long history. Recent clinical applications include anti-inflammatory agents for the treatment of rheumatoid arthritis (chrysotherapy), and is currently being developed as potential anticancer chemotherapeutics. Gold(III), being isoelectronic to platinum(II) as in cisplatin, is of great interest but it is inherently unstable and redox-reactive under physiological conditions. Coordination ligands containing C and/or N donor atom(s) such as porphyrin, pincer-type cyclometalated and/or N-heterocyclic carbene (NHC) can be employed to stabilize gold(III) ion for the preparation of anticancer active compounds. In this review, we described our recent work on the anticancer properties of gold(III) compounds and the identification of molecular targets involved in the mechanisms of action. We also summarized the chemical formulation strategies that have been adopted for the delivery of cytotoxic gold compounds, and for ameliorating the in vivo toxicity.
Persistent Identifierhttp://hdl.handle.net/10722/302371
ISSN
2020 Impact Factor: 5.221
2020 SCImago Journal Rankings: 1.027
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorTong, KC-
dc.contributor.authorHu, D-
dc.contributor.authorWan, PK-
dc.contributor.authorLok, CN-
dc.contributor.authorChe, CM-
dc.date.accessioned2021-09-06T03:31:20Z-
dc.date.available2021-09-06T03:31:20Z-
dc.date.issued2020-
dc.identifier.citationFrontiers in Chemistry, 2020, v. 8, p. article no. 587207-
dc.identifier.issn2296-2646-
dc.identifier.urihttp://hdl.handle.net/10722/302371-
dc.description.abstractThe use of gold in medicine has a long history. Recent clinical applications include anti-inflammatory agents for the treatment of rheumatoid arthritis (chrysotherapy), and is currently being developed as potential anticancer chemotherapeutics. Gold(III), being isoelectronic to platinum(II) as in cisplatin, is of great interest but it is inherently unstable and redox-reactive under physiological conditions. Coordination ligands containing C and/or N donor atom(s) such as porphyrin, pincer-type cyclometalated and/or N-heterocyclic carbene (NHC) can be employed to stabilize gold(III) ion for the preparation of anticancer active compounds. In this review, we described our recent work on the anticancer properties of gold(III) compounds and the identification of molecular targets involved in the mechanisms of action. We also summarized the chemical formulation strategies that have been adopted for the delivery of cytotoxic gold compounds, and for ameliorating the in vivo toxicity.-
dc.languageeng-
dc.publisherFrontiers Media SA. The Journal's web site is located at http://www.frontiersin.org/chemistry-
dc.relation.ispartofFrontiers in Chemistry-
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectgold(III)-
dc.subjectporphyrin-
dc.subjectN-heterocyclic carbene-
dc.subjectanticancer-
dc.subjectbiomolecular target-
dc.titleAnticancer Gold(III) Compounds With Porphyrin or N-heterocyclic Carbene Ligands-
dc.typeArticle-
dc.identifier.emailHu, D: hudi@HKUCC-COM.hku.hk-
dc.identifier.emailChe, CM: chemhead@hku.hk-
dc.identifier.authorityLok, CN=rp00752-
dc.identifier.authorityChe, CM=rp00670-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fchem.2020.587207-
dc.identifier.pmid33240849-
dc.identifier.pmcidPMC7677586-
dc.identifier.scopuseid_2-s2.0-85096370154-
dc.identifier.hkuros324864-
dc.identifier.volume8-
dc.identifier.spagearticle no. 587207-
dc.identifier.epagearticle no. 587207-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats